Tendyne Announces First Patient Enrolled in US Trans-Catheter Mitral Valve Replacement Trial
Tendyne Holdings, Inc. ("Tendyne") a privately held clinical stage medical device company, announced today the Tendyne Bioprosthetic Mitral Valve was successfully implanted in the first patient in the United States as part of a multi-center global feasibility study that aims to provide early insights into the safety and performance of the Tendyne Bioprosthetic Mitral Valve System in patients with symptomatic mitral regurgitation of degenerative or functional etiology.
Tendyne Holdings, Inc.
2825 Fairview Avenue North
Roseville MN 55113
©2014 Tendyne Holdings, Inc.
Tendyne’s products are not approved for investigational use or sale in the United States.